STOCK TITAN

MAIA Biotechnology, Inc. - MAIA STOCK NEWS

Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.

MAIA Biotechnology, Inc. (symbol: MAIA) is a pioneering clinical-stage biopharmaceutical company with a strong focus on targeted immunotherapies for cancer. Headquartered in Chicago, this privately-held company is driven by a dedicated management team with extensive experience in drug development. MAIA Biotechnology is committed to creating first-in-class drugs with novel mechanisms of action aimed at significantly improving and extending the lives of cancer patients.

At the core of MAIA's operations is the development of innovative therapies such as THIO, a promising cancer telomere-targeting agent currently undergoing clinical trials for the treatment of telomerase-positive cancer cells. The company's strategy is to build a diverse portfolio of potentially breakthrough compounds, each with unique mechanisms of action and potential efficacy across various tumor types. This approach not only mitigates risk but also enhances the opportunity for success in the competitive biopharmaceutical landscape.

MAIA’s unique business model involves placing drug candidates into their specialized, R&D-focused subsidiary companies. These subsidiaries are supported by a common infrastructure, making the overall operation more efficient and focused. This structure allows MAIA to concentrate on advancing its most promising agents into human clinical trials, ensuring that the most effective therapies reach patients as swiftly as possible.

In recent developments, MAIA has made significant strides in its clinical programs, securing valuable partnerships and achieving critical milestones. These advances demonstrate the company's unwavering commitment to innovation and excellence in oncology treatment. Investors and stakeholders can stay informed of MAIA’s latest news, achievements, and ongoing projects, which reflect the company's potential for future growth and impact in the field of cancer treatment.

Rhea-AI Summary
MAIA Biotechnology, Inc. announced Chairman and CEO Vlad Vitoc will present at two investor conferences in April. MAIA's lead candidate, THIO, a telomere-targeting anticancer agent, shows promise in NSCLC Phase 2 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
conferences
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announces significant support from board members in recent private placement. Independent directors Cristian Luput and Ramiro Guerrero made notable purchases of common stock. The private funding round closed on March 11th, with strong participation from key board members, showcasing confidence in MAIA's cancer immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.29%
Tags
none
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announces independent directors' share purchases in a recent private placement, reflecting confidence in the company's progress. Ms. Adelina Louie Ngar Yee bought 170,940 shares, emphasizing MAIA's potential in developing cancer immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
none
Rhea-AI Summary
MAIA Biotechnology, Inc. announces a private placement of 578,643 shares of common stock at $2.295 per share to accredited investors, including warrants. The warrants are exercisable after six months and have a term of five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
none
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announced a private placement of common stock and warrants, raising approximately $2.9 million. Independent director Mr. Stan V. Smith, Ph.D. purchased 170,940 shares. The Company's immuno-oncology therapies targeting difficult-to-treat cancers received support from five independent directors, showcasing confidence in the science and clinical pathways.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.76%
Tags
none
-
Rhea-AI Summary
MAIA Biotechnology appoints Professor Saadettin Kilickap, M.D., an accomplished researcher, to its Scientific Advisory Board, enhancing its cancer research capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.58%
Tags
management
Rhea-AI Summary
MAIA Biotechnology, Inc. announced its participation in the 36th Annual ROTH Conference to present its lead candidate THIO, a telomere-targeting anticancer agent showing promising results in non-small cell lung cancer. The Phase 2 trial is nearing completion with strong response rates and potential FDA accelerated approval in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
conferences
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announces promising results of THIO and ionizing radiation combination for childhood brain cancer treatment at AACR Annual Meeting. The study shows significant decrease in cell proliferation and potent anticancer effects in treatment-resistant DIPG.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announces positive efficacy data for the combination of THIO 180mg + cemiplimab in third-line treatment of non-small cell lung cancer (NSCLC), achieving a 38% overall response rate (ORR) which significantly exceeds the standard of care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
Rhea-AI Summary
MAIA Biotechnology, Inc. announces progress in THIO-101 Phase 2 trial with survival and response data expected soon. The company explores various cancer indications and next-gen molecules. Shareholder Letter by CEO Vlad Vitoc details immuno-oncology candidates and pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
none

FAQ

What is the current stock price of MAIA Biotechnology (MAIA)?

The current stock price of MAIA Biotechnology (MAIA) is $2.38 as of January 7, 2025.

What is the market cap of MAIA Biotechnology (MAIA)?

The market cap of MAIA Biotechnology (MAIA) is approximately 63.0M.

What does MAIA Biotechnology, Inc. specialize in?

MAIA Biotechnology specializes in developing first-in-class drugs with novel mechanisms of action, primarily focused on targeted immunotherapies for cancer.

What is MAIA Biotechnology's core drug development program?

MAIA's core program is THIO, a potential cancer telomere-targeting agent in clinical development for treating telomerase-positive cancer cells.

Where is MAIA Biotechnology headquartered?

MAIA Biotechnology is headquartered in Chicago.

What is MAIA's business model?

MAIA's business model involves placing drug candidates into dedicated, R&D-focused subsidiary companies, which are supported by a common infrastructure.

How does MAIA Biotechnology manage risk in its drug development process?

MAIA manages risk by diversifying its portfolio with various compounds that have novel mechanisms of action and potential effectiveness across multiple tumor types.

Who leads MAIA Biotechnology?

MAIA is led by a passionate and experienced management team with significant expertise in drug development.

What recent achievements has MAIA Biotechnology made?

MAIA has made significant strides in its clinical programs, securing valuable partnerships and achieving critical milestones in cancer treatment development.

Is MAIA Biotechnology a public or private company?

MAIA Biotechnology is a privately-held company.

How can I stay updated with the latest news about MAIA Biotechnology?

You can stay updated with the latest news by following MAIA Biotechnology on stock market websites like StockTitan and other financial news platforms.
MAIA Biotechnology, Inc.

NYSE:MAIA

MAIA Rankings

MAIA Stock Data

63.04M
21.92M
17.49%
7.51%
2.76%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHICAGO